Search
Oprozomib
go.drugbank.com/drugs/DB11991InvestigationalOprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS
Demegestone
go.drugbank.com/drugs/DB13857ExperimentalIt was previously marketed in France as Lutionex, but has since been discontinued.
Milatuzumab
go.drugbank.com/drugs/DB12943InvestigationalMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
Rovalpituzumab tesirine
go.drugbank.com/drugs/DB13017InvestigationalRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
PEP0101
go.drugbank.com/drugs/DB18572ExperimentalPEP0101 is a nanocomplex consisting of elastin-like polypeptides and a small interfering RNA (siRNA) designed to down-regulate the expression of EVI1 oncogene in cancer cells.
Synonyms: Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.TN-201
go.drugbank.com/drugs/DB18700InvestigationalTN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalIt is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
Synonyms: (1'R,4R)-2-(2,2,2-trifluoroethyl)-5'-[(E)-3-[4-(trifluoromethyl)piperidin-1-yl]prop-1-enyl]spiro[1,2,5-thiadiazolidine-4,13'-tricyclo[8.2.1.03,8]trideca-3(8),4,6-triene] 1,1-dioxideJLK-247
go.drugbank.com/drugs/DB17637ExperimentalJLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.[L46686]
CS1 CAR-T
go.drugbank.com/drugs/DB33915ExperimentalCS1 CAR-T is under investigation in clinical trial NCT07809594 (CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma).
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX...